Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients (BRAid GBM) Pilot Study

NCT07908147 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07908147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients (BRAid GBM) Pilot Study
Lead sponsor
Olivia Newton-John Cancer Research Institute
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
March 31, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm), idh wildtype glioblastoma

Arms

As registered; 3 arms.

  • BRAF-altered ExperimentalPlixorafenib

    Plixorafenib 900 mg orally once daily continuously

  • NTRK fusion-positive ExperimentalLarotrectinib

    Larotrectinib 100 mg orally twice daily continuously

  • Mismatch repair deficient ExperimentalCadonilimab

    Cadonilimab 6 mg/kg intravenously on Days 1 and 15

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Feasibility of Rapid Molecular Profiling and Matched Targeted Therapy From enrollment to initiation of chemoradiation (pre-treatment period).

    To assess the feasibility of performing rapid molecular profiling before chemoradiation and initiating matched targeted therapy in patients with actionable molecular alterations.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Larotrectinib 20 Orange Book patentsPatent cliff May 16, 2037 (Orange Book patent)
    • US 11337967; expires May 16, 2037; assignee BOW RIVER LLC
    • US 11974998; expires May 16, 2037; assignee BOW RIVER LLC
    • US 10045991; expires April 4, 2037; assignee Loxo Oncology, Inc.
    • US 10137127; expires April 4, 2037; assignee Loxo Oncology, Inc.
    • US 10668072; expires April 4, 2037; assignee Loxo Oncology, Inc.
    • +15 more patents

Lead sponsor's other trials

Olivia Newton-John Cancer Research Institute, most recent start first.

Similar trials

Same condition (Glioblastoma) and phase, most recent start first.